-transparent.png){kind=logo}
Interferon-beta serine (IFN-beta ser) was administered intravenously (i.v.) daily for 14 days at doses of 3, 10, 30 X 10(6) units to 19 patients. In this Phase I trial, IFN-beta ser was tolerated without limiting fever or subjective toxicities. At 30 X 10(6) units, 3 patients developed hematologic toxicity and dose escalation was thus terminated. No patient developed detectable binding or neutralizing antibody to IFN-beta. A significant (p less than 0.006) increase in serum beta 2-microglobulin and a significant (less than 0.005) increase in 2',5'-oligoadenylate synthetase (2-5A) in peripheral mononuclear cells were identified. Increase in these proteins did not correlate with dose or with the disappearance of serum IFN over the first 5 h after injection. Two patients, one with renal carcinoma and one with melanoma, had objective responses. This trial further confirms safety and biological potency of this synthetic mutant of IFN-beta.
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
November 1996,
British journal of cancer,
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
May 1998,
Clinical cancer research : an official journal of the American Association for Cancer Research,
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
August 1988,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
September 2002,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
October 1992,
Journal of interferon research,
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
September 2003,
Clinical cancer research : an official journal of the American Association for Cancer Research,
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
April 1989,
Journal of biological response modifiers,
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
April 1994,
Journal of interferon research,
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
May 1987,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E C Borden, and
M J Hawkins, and
K M Sielaff, and
B M Storer, and
J D Schiesel, and
R V Smalley
December 1990,
Journal of biological response modifiers,
